Scinai Immunotherapeutics Ltd. has announced that CEO Amir Reichman will represent the company at the BIO International Convention 2025, to be held from 16–19 June in Boston. The event will serve as a platform to highlight Scinai’s recent operational, financial, and
Scinai Immunotherapeutics Ltd. has provided contract manufacturing support to U.S.-based biopharmaceutical company Serpin Pharma for a Phase 2 clinical trial of its lead candidate, SP16. The study was conducted across Germany and Israel, marking the first time an international client used
Scinai Immunotherapeutics Ltd. has received regulatory clearance from the Italian government to proceed with its option to acquire Pincell S.r.l., an Italian biotechnology company. The approval falls under Italy’s Golden Power regulation (Law Decree No. 21/2012), which allows the government to
Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on inflammation and immunology (I&I) biological products and contract manufacturing, has signed a binding option agreement to acquire Italian biotech firm Pincell srl. The agreement aligns with Scinai’s strategy to advance novel therapies
Scinai Immunotherapeutics has announced a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. The agreement grants Scinai the right, but not the obligation, to sell up to $10 million in American Depository
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has announced the establishment of a U.S.-based subsidiary, Scinai Bioservices Inc., incorporated in Delaware. The new unit will focus on providing contract development and manufacturing (CDMO) services to early-stage biotech companies, addressing a critical gap
